QDEL

QuidelOrtho Corporation operates as a global provider of in vitro diagnostics, manufacturing and distributing diagnostic testing solutions and transfusion medicine products. Headquartered in San Diego, California, the company was formed through the March 2022 merger of Quidel Corporation and Ortho Clinical Diagnostics, creating a combined entity with approximately 6,000 employees worldwide. The company operates through four primary segments: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. Its product portfolio includes the Vitros family of clinical chemistry systems, Ortho Vision automated immunoassay platforms, Sofia fluorescent immunoassay analyzers, and Savanna molecular diagnostic instruments. QuidelOrtho serves hospitals, clinical laboratories, physician offices, and blood banks across more than 130 countries. The company holds leading positions in transfusion medicine screening and maintains a significant presence in point-of-care infectious disease testing, particularly for influenza and strep throat. Following the merger, QuidelOrtho has focused on integrating operations, optimizing its manufacturing footprint, and expanding its menu of diagnostic assays. The company generates annual revenues exceeding $2 billion and maintains manufacturing facilities in the United States, Europe, and Asia. QuidelOrtho competes with major diagnostic companies including Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, differentiating itself through its specialized expertise in immunoassay technology and transfusion diagnostics.